Controlling immune responses in transplanted tissue using genetic engineering
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation
This study is testing a new type of transplant that uses special genetic engineering to help doctors better monitor and reduce the chances of the body rejecting the graft, making it safer and more effective for patients needing tissue transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11131352 on NIH RePORTER |
What this research studies
This research focuses on developing genetically engineered vascular composite allografts (VCA) to improve the detection of immune rejection and reduce the body's immune response during transplantation. By using a genetic construct that acts as a biosensor, the graft can report on its immunologic state and respond therapeutically to prevent rejection. The study will utilize a porcine model to test these engineered grafts, aiming to enhance the preservation and functionality of transplanted tissues. The approach combines advanced genetic modification techniques with machine perfusion protocols to ensure the grafts remain viable during the transplantation process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals requiring vascular composite allografts, such as those needing reconstructive surgery after trauma or congenital defects.
Not a fit: Patients who do not require vascular composite allografts or those with contraindications for transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved outcomes for patients receiving organ transplants by reducing the risk of rejection and enhancing graft survival.
How similar studies have performed: Previous research has shown promise in using genetic engineering for graft preservation and immune response modulation, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Uygun, Korkut — Massachusetts General Hospital
- Study coordinator: Uygun, Korkut
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.